Squarepoint Ops LLC Has $6.42 Million Stock Holdings in Surmodics, Inc. (NASDAQ:SRDX)

Squarepoint Ops LLC boosted its holdings in Surmodics, Inc. (NASDAQ:SRDX - Free Report) by 154.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 162,066 shares of the company's stock after buying an additional 98,489 shares during the quarter. Squarepoint Ops LLC owned 1.13% of Surmodics worth $6,418,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of SRDX. R Squared Ltd acquired a new stake in shares of Surmodics during the fourth quarter worth $55,000. Legal & General Group Plc raised its holdings in shares of Surmodics by 34.2% during the fourth quarter. Legal & General Group Plc now owns 3,452 shares of the company's stock valued at $137,000 after acquiring an additional 880 shares during the period. Price T Rowe Associates Inc. MD purchased a new stake in shares of Surmodics in the 4th quarter valued at approximately $217,000. Polymer Capital Management US LLC purchased a new stake in shares of Surmodics in the 4th quarter valued at approximately $255,000. Finally, DeepCurrents Investment Group LLC acquired a new position in Surmodics in the 4th quarter worth approximately $260,000. Institutional investors own 96.63% of the company's stock.

Analyst Upgrades and Downgrades

SRDX has been the topic of several recent analyst reports. Wall Street Zen initiated coverage on shares of Surmodics in a research note on Monday, February 3rd. They set a "hold" rating on the stock. Needham & Company LLC reissued a "hold" rating on shares of Surmodics in a research report on Wednesday, April 30th. Finally, Lake Street Capital raised Surmodics from a "hold" rating to a "buy" rating and set a $43.00 price objective for the company in a research note on Friday, March 7th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat.com, Surmodics currently has an average rating of "Hold" and a consensus price target of $43.00.

Surmodics Stock Up 1.2%

Shares of NASDAQ:SRDX traded up $0.35 during trading on Thursday, reaching $29.55. 29,229 shares of the company traded hands, compared to its average volume of 277,874. The firm has a fifty day simple moving average of $28.76 and a 200 day simple moving average of $33.69. The firm has a market cap of $422.54 million, a P/E ratio of -29.23 and a beta of 1.32. Surmodics, Inc. has a 1-year low of $26.00 and a 1-year high of $42.44. The company has a quick ratio of 4.29, a current ratio of 5.45 and a debt-to-equity ratio of 0.26.

Surmodics (NASDAQ:SRDX - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.07). Surmodics had a negative net margin of 11.48% and a negative return on equity of 4.39%. The firm had revenue of $28.09 million for the quarter, compared to analyst estimates of $32.23 million. Analysts anticipate that Surmodics, Inc. will post 0.2 earnings per share for the current fiscal year.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).